SCHEMBL3295285

SCHEMBL3295285

CC(C)C[C@H](C=O)NC(=O)OCc1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
PSMB1 P20618 1/20 0.67
PSMB5 P28074 1/20 0.67
PSMB2 P49721 1/20 0.67
CTSB P07858 6/20 0.62
CTSK P43235 9/20 0.61
CTSL P07711 5/20 0.58
CTSS P25774 3/20 0.57
ATM Q13315 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3291391 1.00 PSMB1 (0.67) PSMB1PSMB5PSMB2CTSBCTSK
SCHEMBL3327332 1.00 PSMB1 (0.67) PSMB1PSMB5PSMB2CTSBCTSK
SCHEMBL3054703 0.90 PSMB1 (0.78) PSMB1PSMB5PSMB2CTSBCTSK
SCHEMBL8971981 0.90 PSMB1 (0.78) PSMB1PSMB5PSMB2CTSBCTSK
SCHEMBL1014661 0.90 PSMB1 (0.78) PSMB1PSMB5PSMB2CTSBCTSK
SCHEMBL7710728 0.90 PSMB1 (0.78) PSMB1PSMB5PSMB2CTSBCTSK
SCHEMBL14341578 0.89 PSMB1 (0.61) PSMB1PSMB5PSMB2CTSBCTSK
Mg-132 SCHEMBL14579851 0.89 PSMB1 (0.77) PSMB1PSMB5PSMB2CTSBCTSK
Mg-132 SCHEMBL2522088 0.89 PSMB1 (0.77) PSMB1PSMB5PSMB2CTSBCTSK
Mg-132 SCHEMBL13436259 0.89 PSMB1 (0.77) PSMB1PSMB5PSMB2CTSBCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3656782-A1 PEPTIDE AMIDE COMPOUND AND PREPARATION METHOD AND MEDICAL USE THEREOF Sichuan Haisco Pharmaceutical Co., Ltd. (CN) 2020-05-27 EP disclosed
US-7727956-B2 Deoxonadepsipeptides AICURIS GMBH & CO. KG (DE) 2010-06-01 US disclosed
US-7727956-B2 Deoxonadepsipeptides AICURIS GMBH & CO. KG (DE) 2010-06-01 US disclosed
US-7727956-B2 Deoxonadepsipeptides AICURIS GMBH & CO. KG (DE) 2010-06-01 US disclosed
EP-1805212-B1 DESOXO-NONADEPSIPEPTIDES AICURIS GMBH & CO KG (DE) 2009-06-10 EP disclosed
US-20080058253-A1 Deoxononadepsipeptides AICURIS GMBH & CO. KG (DE) 2008-03-06 US disclosed
US-20080058253-A1 Deoxononadepsipeptides AICURIS GMBH & CO. KG (DE) 2008-03-06 US disclosed
US-20080058253-A1 Deoxononadepsipeptides AICURIS GMBH & CO. KG (DE) 2008-03-06 US disclosed
EP-1805212-A1 DESOXO-NONADEPSIPEPTIDES AiCuris GmbH & Co. KG (DE) 2007-07-11 EP disclosed
WO-2006042655-A1 DESOXO-NONADEPSIPEPTIDES AICURIS GMBH & CO. KG (DE) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058253-A1 Deoxononadepsipeptides VIP, DNPEP, NPPA PSMB1 3716/4885PSMB5 3452/4885PSMB2 3277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.